Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gastrointestinal 1Dermatologic 1

Conditions

Mastocytosis, Systemic 4Neoplasm Metastasis 2Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Sarcoma 1Recurrence 1Neoplasm, Residual 1Melanoma 1Mastocytosis 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Mast-Cell 1Glioma 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Bevacizumab 119Fluorouracil 91Leucovorin 83Cetuximab 83Oxaliplatin 80pembrolizumab 70Irinotecan 67Nivolumab 46Capecitabine 43Specimen Handling 40regorafenib 30Folfox protocol 29trifluridine tipiracil drug combination 28Magnetic Resonance Spectroscopy 27Biopsy 27Panitumumab 26Standard of Care 25HMPL-013 25IFL protocol 21Gemcitabine 20Blood Specimen Collection 19atezolizumab 18Trifluridine 18Cisplatin 18tislelizumab 17balstilimab 16Colonoscopy 16Carboplatin 16encorafenib 15Paclitaxel 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × avapritinib × 1 year × Clear all
NCT04771520 2026-03-02

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
DermatologicGastrointestinalSarcomaThoracic

Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡